Alectinib price in Bangladesh (2026)
Bangladesh list prices converted into BDT, plus the registration rules of the DGDA, the legal import routes and the real cost build-up for Bangladesh.
Quick answer: alectinib price in Bangladesh
Bangladeshi list price for generic alectinib150 mg is BDT 500–BDT 500 per unit (about BDT 500–BDT 500), i.e. BDT 15,000–BDT 15,000 per 30-unit month; add freight, duty and distributor margin for $Bangladesh. The originator Alecensa lists at BDT 2,082 (about BDT 2,082) per unit, so the cheapest generic saves 76%.
FX basis: 1 USD = 122.87 BDT (September 2026). Conversions are indicative only — the binding price is your supplier quotation.
Currency conversion
| Item | BDT | BDT | USD |
|---|---|---|---|
| Lowest unit price | BDT 500 | BDT 500 | US$4.07 |
| Highest unit price | BDT 500 | BDT 500 | US$4.07 |
| 30-unit month (lowest) | BDT 15,000 | BDT 15,000 | US$122.08 |
| 30-unit month (highest) | BDT 15,000 | BDT 15,000 | US$122.08 |
| Originator unit price | BDT 2,082 | BDT 2,082 | US$16.94 |
Bangladesh benchmark (world reference price)
Registered brands and list prices for this molecule in Bangladesh (DGDA registration, via MedEx).
| Brand | Manufacturer | Strength | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Alecnib Lowest | Everest Pharmaceuticals Ltd. | 150 mg Capsule | BDT 500 | US$4.07 | 1 x 56: ৳ 28,000.00 |
| Alecensa Originator | Roche Bangladesh Ltd. | 150 mg Capsule | BDT 2,082 | US$16.94 | 7 x 8: ৳ 116,592.00 |
Source: MedEx Bangladesh drug registry (list prices of DGDA-registered brands). Unit prices move with pack size, pharmacy and exchange rate — reference only. Original registry page
Import and regulatory notes
Directorate General of Drug Administration (DGDA). Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT.
How to obtain it legally
- Obtain a prescription plus the diagnostic/genetic report from the treating physician (e.g. the target-mutation result).
- Confirm the exact brand and strength, and ask the supplier for the batch number, certificate of analysis (COA) and the manufacturer's GMP credentials.
- Clear the shipment through a DGDA-licensed importer or pharmacy; unregistered products go through the named-patient route.
- Check batch number, expiry and packaging on arrival, then follow the prescriber's monitoring schedule.
What adds to the price when you import
- International freight and cold chain (monoclonal antibodies and insulins need 2–8°C end-to-end).
- Customs duty and import VAT in Bangladesh.
- Compliance, licensing and warehousing cost of the importer/distributor (typically 10–30%).
- Order size and pack configuration — full cases price below retail strips.
- Exchange-rate movement: this page converts at 1 USD = 122.87 BDT.
Availability in Southeast Asia
| Country | Status | Notes |
|---|---|---|
| Bangladesh (regional supply hub) | Available | One domestic generic (Everest's Alecnib) priced at roughly a quarter of the Roche originator price per capsule; Everest also lists alectinib among its oncology export products |
Frequently asked questions
How much does alectinib cost in Bangladesh?
There is no fixed public retail price for alectinib in Bangladesh in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 500–BDT 500 (US$4.07–US$4.07) per unit, about BDT 500–BDT 500 in BDT per unit and BDT 15,000–BDT 15,000 per 30-unit month, before freight, customs duty and distributor margin.
Can I legally import alectinib into Bangladesh?
Yes, but only through the rules of the Directorate General of Drug Administration (DGDA): Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.
Are Bangladeshi or Indian generics of alectinib approved in Bangladesh?
We cannot confirm the registration status of every individual generic brand in Bangladesh. Directorate General of Drug Administration (DGDA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.
Why is the Bangladesh price a useful reference?
Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.
What is the availability situation for alectinib in Bangladesh?
Bangladesh (regional supply hub): Available. One domestic generic (Everest's Alecnib) priced at roughly a quarter of the Roche originator price per capsule; Everest also lists alectinib among its oncology export products
This molecule in other markets
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Also sourced for Bangladesh
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.